Document is current
Any future updates will be listed below
-
Authors
Ishikawa, Tomoki
Kako, Akihito
Sato, Jumpei
Hattori, Junko
Yoshimoto, Hiromasa
Kitsuregawa, Masaru
Goda, Kazuo
Takahashi, Yoshimitsu
Nakayama, Takeo
Mitsutake, Naohiro
-
Funding
Funding for this research was provided by:
the Health Care Science Institute Research Grant
Progress of the next Cross-ministerial Strategic Innovation Promotion Program on “Integrated Health Care System(C-1)” (JPJ012425)
Japan Agency for Medical Research and Development (JP18lk1010033h0001)
- License Information
-
More Information
Article History
Received: 19 November 2024
Accepted: 23 April 2025
First Online: 19 May 2025
Declarations
:
: Our study was approved by the Ethics Committee of Institute for Health Economics and Policy (approval number: R4-010). The requirement for informed consent was waived because of the anonymized nature of the data in the database.
: Not applicable.
: TN reports grants or contracts: I&H Co., Ltd.; Cocokarafine Group Co., Ltd.; KonicaMinolta, Inc.; NTT DATA; consulting fees: Ohtsuka Pharmaceutical Co.; Takeda Pharmaceutical Co.; Johnson & Johnson K.K.; AstraZeneca plc; Nippon Zoki Pharmaceutical Co., Ltd.; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Pfizer Japan Inc.; MSD K.K.; Chugai Pharamaceutical Co.; Takeda Pharmaceutical Co.; Janssen Pharmaceutical K.K.; Boehringer Ingelheim International GmbH.; Eli Lilly Japan K.K.; Maruho Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Novartis Pharma K.K.; Allergan Japan K.K.; Novo Nordisk Pharma Ltd.; TOA EIYO Ltd.; AbbVie Inc.; ONO PHARMACEUTICAL CO., LTD.;GSK plc; Alexion Pharmaceuticals, Inc.; Cannon Medical Systems Co.; Kowa Company, Limited; Araya; Merck Co.; Amicus Therapeutics, Inc.; stock options: BonBon inc.; donation: CancerScan; JMDC Inc. YT is employed through a joint research fund between Kyoto University and HealthTech Laboratory Inc.
